Autologous Large Multivalent Immunogen Vaccine in Patients With Metastatic Melanoma and Renal Cell Carcinoma

Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware St. SE, MMC 480, Minneapolis, MN 55455, USA.
American journal of clinical oncology (Impact Factor: 3.06). 05/2008; 31(2):173-81. DOI: 10.1097/COC.0b013e3181573e6b
Source: PubMed


To evaluate the safety and activity of large multivalent immunogen (LMI), prepared by immobilizing autologous tumor cell plasma membrane on 5-microm diameter silica beads, in patients with melanoma and renal cell carcinoma (RCC).
Thirty patients with stage IV metastatic melanoma and 31 patients with stage IV RCC were randomly assigned to 1 of 3 trial arms and received monthly treatment with (1) LMI alone, (2) cyclophosphamide followed 8 days later with LMI, or (3) the same treatment as in arm 2 with IL-2 given for 5 days beginning 1 week after LMI administration.
No grade 4 toxicities were observed. For patients with melanoma, median overall survival time for all 30 patients was 20.4 months [95% confidence interval (CI): 8.0-not assessable], and median progression-free survival was 2.8 months (95% CI: 1.9-6.3). For patients with RCC, median overall survival exceeded 46.2 months (95% CI: 30.3-not assessable), and median progression-free survival was 12.2 months (95% CI: 4.6-not assessable). Two patients had a partial response to LMI treatment.
Based on our results that demonstrate the safety and tolerability of LMI vaccine, further development of this therapy is warranted to evaluate its clinical efficacy.

8 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Doelstelling: Er is hernieuwde interesse voor immunotherapie als behandeling voor gemetastaseerd niercelcarcinoom (NCC). Deze studie had als doel te bepalen of radiofrequente ablatie (RFA) gecombineerd met interleukine-2 (IL-2) een tumorspecifieke immuunrespons kan opwekken tegen NCC. Materiaal en methode: Muizen met getransplanteerde niertumoren werden behandeld met een combinatietherapie van RFA en IL-2, RFA of IL-2 als monotherapie, of geen behandeling (controle). De aanwezigheid van immunogene cellen in de primaire tumor werd bepaald door middel van immunohistochemie. In vitro cytotoxiciteit assays werden uitgevoerd met CD8+ T- en natural killer (NK) cellen uit de milt van behandelde muizen. Longmetastasen werden geïnduceerd door middel van intraveneuze injectie van tumorcellen voor of na de behandeling, waarna macroscopische longmetastasen werden gekwantificeerd. Resultaten: NK-, CD4+ en CD8+ T-cellen waren significant frequenter aanwezig in tumorweefsel van RFA/IL-2 behandelde muizen (p < 0,0001). Zowel NK- als CD8+ T-cellen uit de milt van de muis gaven een sterke antitumoractiviteit in vitro na behandeling met RFA/IL-2. Behandeling met RFA/ IL-2 gaf een significante preventie van longmetastasen (p < 0,0001). Bestaande longmetastasen waren kleiner in muizen die waren behandeld met RFA/IL-2 (p = 0,025) ten opzichtevan muizen die waren behandeld met IL-2. Conclusie: RFA van de primaire niertumor gecombineerd met IL-2 induceert een antitumoreffect tegen NCC dat veel sterker is dan het effect van IL-2 als monotherapie. Zowel NKals CD8+ T-cellen lijken een belangrijke rol te spelen bij dit effect. Deze therapie kan een belangrijke rol spelen in de ontwikkeling van nieuwe immunotherapeutische behandelingen voor NCC.
    No preview · Article · Oct 2012
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The authors describe a control system for a binocular image acquisition mechanism, for use in mobile robotic systems, which allows shifts in focus of attenuation to be made in a natural, device-independent manner. The control method is based on the modal control technique proposed by R.W. Brockett (Proc. IEEE Robotics Autom. Conf., 1988). The shifts are accomplished by altering the feedback gains applied to the visual feedback paths in the position and velocity control loops of the binocular camera system. By altering these gains, a feature-selection operation can be performed by which the saliency of a given feature is enhanced, while the saliency of other features is reduced. Two experiments performed with the system to demonstrate modal control of attention are discussed
    Full-text · Conference Paper · Jun 1989
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immunotherapy for cancer has remained in the experimental stage for more than a century. This lengthy duration reflects as much the scope of failures in the area as it does the continuous and remarkable expansion of the understanding of immune responses and host-tumor interaction. Immunotherapy for cancer largely has focused on immunization with peptides or whole antigens, intact tumor cells, or dendritic cells pulsed with antigenic peptides isolated from cancers. Several potential vaccines have been evaluated for the treatment of patients with renal cell cancer. They include heat-shock protein-peptide complex-96, attenuated modified vaccinia Ankara virus encoding 5T4 tumor-associated antigen, dendritic cell pulsed with tumor lysate, dendritic cell-tumor cell hybrid, and irradiated tumor cells admixed with adjuvants. Promising results were obtained in clinical trials, but issues of tumor immunosuppression and lack of identified tumor-associated antigens must be addressed before vaccine therapy can be applied successfully in advanced renal cell cancer.
    No preview · Article · Oct 2008 · Expert Review of Vaccines
Show more